Company news

Ocugen, Inc. news in 2022

Ocugen, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®

December 15, 2022

Ocugen Announces OCU400 Receives Orphan Drug Designations for Retinitis Pigmentosa and Leber Congenital Amaurosis

December 14, 2022

Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell

December 12, 2022

Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis

December 6, 2022

Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit

November 27, 2022

Ocugen Provides Business Update & Third Quarter 2022 Financial Results

November 7, 2022

Ocugen to Host Conference Call on Tuesday, November 8 at 8: 30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results

October 26, 2022

Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022

October 18, 2022

Ocugen Announces Completion of Dosing in OCU400 Phase 1/2 Cohort 2

October 11, 2022

Ocugen, Inc. to Present at Upcoming Vaccines, Cell & Gene Therapy Conferences

October 5, 2022

Ocugen, Inc. to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 28, 2022

Ocugen Announces Agreement With Washington University in St. Louis for Commercialization of Intranasal COVID-19 Vaccine in U.S., Europe, and Japan

September 27, 2022

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 15, 2022

Ocugen Announces Publication of a Comprehensive Review of BBV152 in Frontiers in Immunology

September 13, 2022

Ocugen CSO to Participate in 3rd Annual Gene Therapy for Ophthalmic Disorders Conference

September 7, 2022

Ocugen, Inc. to Present at H.C. Wainwright 24th Annual Global Investment Conference

September 5, 2022

Ocugen Appoints Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, as Chief Medical Officer and Promotes Arun Upadhyay, PhD, to Chief Scientific Officer

August 31, 2022

Ocugen CEO to Present at H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

August 11, 2022

Ocugen Provides Business Update & Second Quarter 2022 Financial Results

August 4, 2022

Ocugen To Host Conference Call on Friday, August 5 at 8: 30 a.m. ET to Discuss Business Updates and Second Quarter 2022 Financial Results

July 28, 2022

Ocugen Announces Publication of Positive Results of COVID-19 Vaccine Trial for Children 2-18 in The Lancet Infectious Diseases

June 20, 2022

Ocugen Named Among Philadelphia’s ‘2022 Best Places to Work’

June 13, 2022

Ocugen, Inc. Announces Issuance of U.S. Patent for Treating Retinal Degenerative Diseases Using Gene Therapy

June 12, 2022

Ocugen, Inc. to Present at BIO International Convention 2022

June 8, 2022

Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

May 23, 2022

Ocugen, Inc. to Present at H.C. Wainwright Global Investment Conference

May 22, 2022

Ocugen Announces FDA Removes Clinical Hold on Phase 2/3 Clinical Trial for COVAXIN™ (BBV152)

May 22, 2022

Ocugen Provides Business Update and First Quarter 2022 Financial Results

May 5, 2022

Ocugen to Host Conference Call on Friday, May 6 at 8: 30 a.m. ET to Provide Business Update and Discuss First Quarter 2022 Financial Results

May 1, 2022

Ocugen, Inc. to Present Preclinical Results at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

April 28, 2022

Ocugen, Inc. Announces Positive DSMB Recommendation for OCU400-101 Clinical Trial

April 24, 2022

Ocugen, Inc. to Present at NobleCon18

April 18, 2022

Ocugen, Inc. to Commercialize COVAXIN™ in Mexico, Rights Now Encompassing All of North America

April 17, 2022

Ocugen, Inc. Provides Update on its Phase 2/3 Study of COVAXIN™ (BBV152)

April 11, 2022

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

March 31, 2022

Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors

March 22, 2022

Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance

March 20, 2022

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 17, 2022

Ocugen, Inc. to Present at the 34th Annual ROTH Conference

March 8, 2022

Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request

March 3, 2022

Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results

February 24, 2022

Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock

February 21, 2022

Ocugen to Host Conference Call on Friday, February 25 at 8: 30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

February 17, 2022

Ocugen, Inc. Announces U.S. FDA Lifts Clinical Hold on the Submission of Its Investigational New Drug Application for Its COVID-19 Vaccine Candidate COVAXIN™ (BBV152)

February 17, 2022

Ocugen/Harris Poll Finds Americans Want More COVID-19 Vaccine Options

February 14, 2022

Ocugen, Inc. Signs Letter of Intent to Acquire Vaccine Manufacturing, R&D Hub in Ontario, Canada

January 26, 2022

Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety

January 23, 2022

Ocugen, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 20, 2022

COVAXIN™ (BBV152) Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

January 11, 2022

COVAXIN™ (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety

January 7, 2022

Older news releases →

Calls in 2022

Decks in 2022